Akebia Therapeutics Updates License Agreement with Medice for Vafseo Supply and Manufacturing
I'm PortAI, I can summarize articles.
Akebia Therapeutics Inc. has amended its License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG for the development and commercialization of Vafseo for anemia in chronic kidney disease patients in Europe and other regions. Akebia will supply vadadustat drug substance to Medice, which will manufacture Vafseo tablets. Any resulting know-how or patent rights will be owned by Akebia. The amendment will be filed with the Annual Report on Form 10-K for 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments